Literature DB >> 25850038

IDO inhibitors move center stage in immuno-oncology.

Cormac Sheridan.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2015        PMID： 25850038     DOI： 10.1038/nbt0415-321

Source DB:  PubMed          Journal:  Nat Biotechnol        ISSN： 1087-0156            Impact factor:   54.908


× No keyword cloud information.
  3 in total

1.  T cell costimulation molecules CD80/86 inhibit osteoclast differentiation by inducing the IDO/tryptophan pathway.

Authors:  Aline Bozec; Mario M Zaiss; Rosebeth Kagwiria; Reinhard Voll; Manfred Rauh; Zhu Chen; Sandra Mueller-Schmucker; Richard A Kroczek; Lucie Heinzerling; Muriel Moser; Andrew L Mellor; Jean-Pierre David; Georg Schett
Journal:  Sci Transl Med       Date:  2014-05-07       Impact factor: 17.956

2.  Evidence for a tumoral immune resistance mechanism based on tryptophan degradation by indoleamine 2,3-dioxygenase.

Authors:  Catherine Uyttenhove; Luc Pilotte; Ivan Théate; Vincent Stroobant; Didier Colau; Nicolas Parmentier; Thierry Boon; Benoît J Van den Eynde
Journal:  Nat Med       Date:  2003-09-21       Impact factor: 53.440

3.  Up-regulation of PD-L1, IDO, and T(regs) in the melanoma tumor microenvironment is driven by CD8(+) T cells.

Authors:  Stefani Spranger; Robbert M Spaapen; Yuanyuan Zha; Jason Williams; Yuru Meng; Thanh T Ha; Thomas F Gajewski
Journal:  Sci Transl Med       Date:  2013-08-28       Impact factor: 17.956
  3 in total
  32 in total

1.  Prognostic Molecular and Imaging Biomarkers in Primary Glioblastoma.

Authors:  Edit Bosnyák; Sharon K Michelhaugh; Neil V Klinger; David O Kamson; Geoffrey R Barger; Sandeep Mittal; Csaba Juhász
Journal:  Clin Nucl Med       Date:  2017-05       Impact factor: 7.794

Review 2.  Targeting Metalloenzymes for Therapeutic Intervention.

Authors:  Allie Y Chen; Rebecca N Adamek; Benjamin L Dick; Cy V Credille; Christine N Morrison; Seth M Cohen
Journal:  Chem Rev       Date:  2018-09-07       Impact factor: 60.622

Review 3.  The application of nanotechnology in enhancing immunotherapy for cancer treatment: current effects and perspective.

Authors:  Yongjiang Li; Ciceron Ayala-Orozco; Pradipta Ranjan Rauta; Sunil Krishnan
Journal:  Nanoscale       Date:  2019-09-18       Impact factor: 7.790

4.  A Dose-escalation Study of Recombinant Human Interleukin-18 in Combination With Ofatumumab After Autologous Peripheral Blood Stem Cell Transplantation for Lymphoma.

Authors:  Michael J Robertson; Christopher W Stamatkin; David Pelloso; Jill Weisenbach; Nagendra K Prasad; Ahmad R Safa
Journal:  J Immunother       Date:  2018-04       Impact factor: 4.456

5.  Cytokine resurrection: engineered IL-2 ramps up immuno-oncology responses.

Authors:  Ken Garber
Journal:  Nat Biotechnol       Date:  2018-05-09       Impact factor: 54.908

Review 6.  Metabolic reprogramming in clear cell renal cell carcinoma.

Authors:  Hiromi I Wettersten; Omran Abu Aboud; Primo N Lara; Robert H Weiss
Journal:  Nat Rev Nephrol       Date:  2017-05-08       Impact factor: 28.314

7.  Phase 1 investigation of lenalidomide/rituximab plus outcomes of lenalidomide maintenance in relapsed CNS lymphoma.

Authors:  James L Rubenstein; Huimin Geng; Eleanor J Fraser; Paul Formaker; Lingjing Chen; Jigyasa Sharma; Phoebe Killea; Kaylee Choi; Jenny Ventura; John Kurhanewicz; Clifford Lowell; Jimmy Hwang; Patrick Treseler; Penny K Sneed; Jing Li; Xiaomin Wang; Nianhang Chen; Jon Gangoiti; Pamela N Munster; Bertil Damato
Journal:  Blood Adv       Date:  2018-07-10

8.  Structural Basis of Inhibitor Selectivity in Human Indoleamine 2,3-Dioxygenase 1 and Tryptophan Dioxygenase.

Authors:  Khoa N Pham; Ariel Lewis-Ballester; Syun-Ru Yeh
Journal:  J Am Chem Soc       Date:  2019-11-14       Impact factor: 15.419

9.  Tumor-associated GM-CSF overexpression induces immunoinhibitory molecules via STAT3 in myeloid-suppressor cells infiltrating liver metastases.

Authors:  M Thorn; P Guha; M Cunetta; N J Espat; G Miller; R P Junghans; S C Katz
Journal:  Cancer Gene Ther       Date:  2016-05-20       Impact factor: 5.987

10.  Exacerbation of Autoimmune Thyroiditis by CTLA-4 Blockade: A Role for IFNγ-Induced Indoleamine 2, 3-Dioxygenase.

Authors:  Rajni Sharma; Giulia Di Dalmazi; Patrizio Caturegli
Journal:  Thyroid       Date:  2016-07-22       Impact factor: 6.568
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.